0.1(top 100%)
impact factor
91(top 100%)
papers
123(top 50%)
citations
5(top 50%)
h-index
0.1(top 100%)
impact factor
106
all documents
131
doc citations
11(top 50%)
g-index

Top Articles

#TitleJournalYearCitations
1Case Report and ReviewUroOncology200340
2Activated Leukocyte Cell Adhesion Molecule (ALCAM) Expression is Associated with a Poor Prognosis for Bladder Cancer PatientsUroOncology200319
3Tolerability of Antiandrogens in the Treatment of Prostate CancerUroOncology200419
4Use of BCG in Immunotherapy of Superficial Bladder Cancer: Multicentric Investigation on Safety and ComplianceUroOncology200311
5Interleukin-1 Receptor Antagonist Polymorphism in Patients with Prostate Cancer and Benign Prostatic Hyperplasia: A Case Control Study from North IndiaUroOncology20046
6Brachytherapy of Prostate Cancer and Sexual DysfunctionUroOncology20034
7Determinants of Accrual to Prostate Cancer Clinical TrialsUroOncology20023
8A Prospective Survey of Surgical Approaches in Clinically Localized Renal Cell Carcinoma--A Preliminary Attempt at Surgical Quality ControlUroOncology20023
9Factors Influencing Patient Survival in a Group of Men with Prostate Cancer in Yaoundé, CameroonUroOncology20033
10Perioperative Homologous Blood Transfusion and Survival in Patients with Surgically Treated Renal Cell CarcinomaUroOncology20033
11Laser Capture Microdissection: Applications in Urological Cancer ResearchUroOncology20023
12The Tipping Point—How Little Things Can Make a Big Difference?Malcolm Gladwell (ed.), New York, Little, Brown and Company 2002, ISBN 0-316-34662-4UroOncology20042
13A Retrospective Analysis of Serum CA 15-3 Concentrations in Patients with Localised or Metastatic Renal Cancer and its Impact on Prognosis and Follow-up. A Single-centre ExperienceUroOncology20022
14Adjuvant Luteinising Hormone-Releasing Hormone (LHRH)—Agonist Therapy in Prostate CancerUroOncology20031
15The Investigation and Management of Haematuria—A Continuing DilemmaUroOncology20031
16Clinicopathological Features of Incidentally Detected Renal Cell Carcinoma in JapanUroOncology20031
17Prognostic Significance of Capsular Invasion and Capsular Penetration in Japanese Men with Prostate Cancer Undergoing Radical Retropubic ProstatectomyUroOncology20041
18Transitional Cell Carcinoma of Kidney with Extension into Renal Vein and Inferior Vena CavaUroOncology20041
19Long-term Outcome of Adjuvant Chemotherapy with MVP-CAB Regimen (Methotrexate, Vincristine, Cisplatin, Cyclophosphamide, Adriamycin and Bleomycin) for Locally Advanced Bladder CancerUroOncology20041
20Retroperitoneal Liposarcoma and Li-Fraumeni Syndrome: A Case Report and Review of Management OptionsUroOncology20041
21Serum HER-2/neu Extracellular Domain Levels in Men Presenting with Suspected Prostate CancerUroOncology20021
22The Correlation of Tissue p53 Protein Overexpression and p53 Antigen in Serum of Patients with Bladder CancerUroOncology20031
23Molecular Genetic Screening for Urine Detection of Bladder CancerUroOncology20021
24Detection of Recurrent Transitional Cell Carcinoma of the Bladder with Nuclear Matrix Protein-22 in a Follow-up SettingUroOncology20031
25IsPSAReliable in Patients with Indwelling Urethral Catheter?UroOncology20031
26Miliary Tuberculosis Following Intravesical BCG TreatmentUroOncology20030
27Dendritic Cell Therapy for Renal Cell CarcinomaUroOncology20030
28On Publication in Peer Reviewed JournalsUroOncology20030
29Are Laparoscopic and Open Radical Nephrectomy Equal in Oncological Effectiveness for Long Term Cancer Control?UroOncology20030
30Case Report: Dural Metastasis in Prostate CancerUroOncology20030
31Editorial: Do Bisphosphonates have a Role in Prostate Cancer?UroOncology20030
32Second Opinion—Doctors Diseases and Decisions in Modern MedicineUroOncology20030
33Intravesical Bacillus Calmette–Guerin (BCG)—A Survey of Practice Patterns of Urologists Across Britain and IrelandUroOncology20030
34Dietary Factors for Prostate CancerUroOncology20030
35Staging of Bladder Carcinoma: MRI—Pathologic CorrelationUroOncology20030
36The Characteristics of Renal Cell Carcinoma Patients, Who may Benefit from Radiotherapy and Post-NephrectomyUroOncology20030
37Prediction of Free PSA, PSA Density and PSA Density Transition Zone in the Outcome of Sextant Prostate Biopsies in Patients with Total PSA between 3 and 15 ng/mlUroOncology20040
38Editorial: Does the Total Number of Specific Procedures Performed by a Surgeon Influence Outcome?UroOncology20040
39Irregular Blurred Mass of the Right Pyelum: A Tumour?UroOncology20040
40The Effect of BCG on Angiogenesis and Cellular Proliferation in Recurrent Superficial TCC of the BladderUroOncology20040
41Angiogenesis and Histologic Scoring in Prostatic Carcinoma—A Valuable Cost Effective Prognostic IndicatorUroOncology20040
42Clinical Outcome and Safety of Bacillus Calmette-Guérin Immunotherapy for Superficial Bladder CancerUroOncology20040
43Editorial: Interleukin-6: A Multifunctional Molecule in Prostate CancerUroOncology20040
44Impact of United Kingdom Cancer Outcome Guidelines on Prostate Cancer Services: Redefining the Role of Urologists and Primary Care TeamsUroOncology20040
45Reproductive Organs Preserving Radical Cystectomy in FemalesUroOncology20040
46Prognostic Significance of Bone Metastasis Patterns in Patients with Prostate CancerUroOncology20040
47Perioperative Advantage of Radical Perineal Prostatectomy over Radical Retropubic ProstatectomyUroOncology20040
48Clinical Outcome and Safety of Bacillus Calmette-Guérin Immunotherapy for Superficial Bladder CancerUroOncology20040
49Case Report: Aggressive Paratesticular Angiomyxoma: An Unusual Locally Aggressive Benign Intrascrotal NeoplasmUroOncology20040
50Outcome of Patients After Radical Retropubic Prostatectomy: A Comparison of Prostate Cancer Diagnosed Using Extended Needle Biopsy Technique vs. Non-extended Needle Biopsy TechniqueUroOncology20040